IL-PRICEFX
30.4.2020 13:02:10 CEST | Business Wire | Press release
Pricefx , the global leader in native cloud pricing software, today announced that it will provide its customers free access to Sales Insights Accelerator. This Accelerator is a preconfigured, easy to deploy, highly actionable pricing analytics solution that can analyze transactional data, quickly gain visibility into pricing opportunities and flag threats. Pricefx is offering free, unlimited access to these products in order to help businesses develop strategies to quickly react to current market dynamics and challenges as a result of COVID-19.
Businesses worldwide have experienced shutdowns and consumers are under strict stay at home orders in an effort to contain the new coronavirus pandemic. This has caused consumer prices to plummet in many industries. In the U.S. consumer prices in March were at the lowest in five years . Supply chain issues continue to challenge many businesses as shortages and plant closures threaten business continuity.
“We feel strongly that we have a responsibility to the community and our customers to help during these challenging times, and while we are not manufacturer who can retool to produce PPE items, we write awesome code that helps our customers get better at pricing every day,” said Marcin Cichon, CEO and co-founder at Pricefx. “While other companies have been quick to provide advice on how to manage during the COVID crisis or to offer free trials, we wanted to give our customers advanced analytical solutions – free of charge and no strings attached – to help them operate through these challenges. Now more than ever, businesses need concrete, continuous and actionable insights into sales and pricing to successfully navigate this market.”
The Insights dashboards give organizations a structured way to see aggregate, macro trends while also providing the flexibility to drill-down into data to uncover insights and outliers. Sales Insights analyzes product and customer profitability and potential margin leakages. Using PriceAnalyzer functionality, Sales Insights includes the following dashboards:
- Revenue and Margin – analyzes the relationship between revenue and margin percentage from different perspectives
- Regional Revenue and Margin by geography – shows key performance indicators in a world or continental map
- Outliers – analyzes the best and worst performing products and customers
- Waterfall – shows the waterfall analysis with grouped adjustments
- Waterfall Comparison – compares waterfall analysis per time, product or customer
- Revenue Breakdown – shows the reasons of the difference in revenue between the two selected periods
- Margin Breakdown –shows the reasons of the difference in margin between the two selected periods
“We believe that this initiative will add real, tangible, strategic value to our customers’ operations,” added Cichon. “It is our hope that these accelerators become a sustainable part of our customers’ daily pricing routine. We are thankful for the continued trust in Pricefx and the opportunity to help.”
Any customer of Pricefx who has Analytics as part of their subscription and has transactional data loaded in Pricefx is eligible to receive this offer, including distribution, installation and productive use, at no cost. Pricefx will also provide advice on the actionable use of the Sales Insights Accelerator, free of charge. Additional Accelerators are in development and will be available in the coming months.
Interested customers should contact their current Pricefx representative for more information.
About Pricefx
Established in 2011 in Germany, Pricefx is the global leader in SaaS pricing software, offering a comprehensive suite of solutions that are fast to implement, flexible to configure and customize, and friendly to learn and use. Pricefx delivers a complete price optimization and management platform based on native cloud architecture, providing industry leading time to value and total cost of ownership advantages to customers. Their innovative solution works for both B2B and B2C enterprises of any size, in any industry, in any part of the world. Pricefx’s business model is entirely based on the satisfaction and loyalty of its customers. Today, Pricefx delivers Passion for Pricing to more than 100 customers in more than 37 countries worldwide. For more information, please visit www.pricefx.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200430005150/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom